ES3062687T3 - Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity - Google Patents
Substituted amide macrocyclic compounds with orexin-2 receptor agonist activityInfo
- Publication number
- ES3062687T3 ES3062687T3 ES22724964T ES22724964T ES3062687T3 ES 3062687 T3 ES3062687 T3 ES 3062687T3 ES 22724964 T ES22724964 T ES 22724964T ES 22724964 T ES22724964 T ES 22724964T ES 3062687 T3 ES3062687 T3 ES 3062687T3
- Authority
- ES
- Spain
- Prior art keywords
- orexin
- receptor agonist
- agonist activity
- substituted amide
- macrocyclic compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179616P | 2021-04-26 | 2021-04-26 | |
| PCT/US2022/026144 WO2022232025A1 (en) | 2021-04-26 | 2022-04-25 | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3062687T3 true ES3062687T3 (en) | 2026-04-13 |
Family
ID=81750587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22724964T Active ES3062687T3 (en) | 2021-04-26 | 2022-04-25 | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240124485A1 (https=) |
| EP (1) | EP4329877B1 (https=) |
| JP (1) | JP2024516633A (https=) |
| CN (1) | CN117440955A (https=) |
| AU (1) | AU2022267220A1 (https=) |
| CA (1) | CA3215210A1 (https=) |
| ES (1) | ES3062687T3 (https=) |
| WO (1) | WO2022232025A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4622712A1 (en) * | 2022-11-23 | 2025-10-01 | Vertex Pharmaceuticals Incorporated | Substituted macrocyclic amine modulators of orexin receptor 2 |
| KR20250139869A (ko) | 2023-01-31 | 2025-09-23 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 거대환식 오렉신 수용체 효능제 및 이의 용도 |
| PE20252742A1 (es) | 2023-03-16 | 2025-12-05 | Takeda Pharmaceuticals Co | Compuestos heterociclicos macrociclicos y sus usos |
| IL324946A (en) | 2023-06-01 | 2026-01-01 | H Lundbeck As | Spiro-macrocyclic orexin 2 receptor agonists |
| WO2025096445A1 (en) | 2023-10-30 | 2025-05-08 | Alkermes, Inc. | Synthesis of intermediates for the preparation of macrocyclic compounds |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2026017128A1 (zh) * | 2024-07-17 | 2026-01-22 | 江苏恩华药业股份有限公司 | 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP1542A (en) * | 1999-04-30 | 2006-01-31 | Pfizer Prod Inc | Glucocorticoid receptor modulators. |
| EP2038255A2 (en) * | 2006-06-16 | 2009-03-25 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted piperidine carboxamides |
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| JP5635991B2 (ja) * | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | イソニコチンアミドオレキシン受容体アンタゴニスト |
| NZ592705A (en) * | 2008-12-10 | 2013-02-22 | Achillion Pharmaceuticals Inc | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| WO2015048091A1 (en) | 2013-09-24 | 2015-04-02 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| EP3068783B1 (en) | 2013-11-15 | 2020-09-23 | The Board of Trustees of the Leland Stanford Junior University | Agonists of hypocretin receptor 2 for use for treating heart failure |
| PE20161064A1 (es) | 2013-12-12 | 2016-10-28 | Univ Tsukuba | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo |
| WO2015147240A1 (ja) | 2014-03-28 | 2015-10-01 | 国立大学法人筑波大学 | 敗血症の予防治療剤 |
| LT3984994T (lt) * | 2016-02-04 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti |
| US11059780B2 (en) * | 2017-03-08 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| EA039459B1 (ru) * | 2017-12-25 | 2022-01-28 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа |
| JP7339250B2 (ja) * | 2018-06-29 | 2023-09-05 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US12312332B2 (en) * | 2019-08-08 | 2025-05-27 | Merck Sharp & Dohme Llc | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| EP4065585B1 (en) * | 2019-11-25 | 2025-08-20 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US12006330B2 (en) * | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
-
2022
- 2022-04-25 CN CN202280038386.8A patent/CN117440955A/zh active Pending
- 2022-04-25 ES ES22724964T patent/ES3062687T3/es active Active
- 2022-04-25 AU AU2022267220A patent/AU2022267220A1/en active Pending
- 2022-04-25 JP JP2023565387A patent/JP2024516633A/ja active Pending
- 2022-04-25 CA CA3215210A patent/CA3215210A1/en active Pending
- 2022-04-25 EP EP22724964.6A patent/EP4329877B1/en active Active
- 2022-04-25 WO PCT/US2022/026144 patent/WO2022232025A1/en not_active Ceased
-
2023
- 2023-10-03 US US18/376,020 patent/US20240124485A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022267220A1 (en) | 2023-10-19 |
| JP2024516633A (ja) | 2024-04-16 |
| CA3215210A1 (en) | 2022-11-03 |
| US20240124485A1 (en) | 2024-04-18 |
| CN117440955A (zh) | 2024-01-23 |
| EP4329877C0 (en) | 2026-02-04 |
| EP4329877B1 (en) | 2026-02-04 |
| WO2022232025A1 (en) | 2022-11-03 |
| EP4329877A1 (en) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3062687T3 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| HRP20190417T1 (hr) | Diamidni spojevi s aktivnošću antagonista muskarinskog receptora i agonista beta 2 adrenergičkog receptora | |
| EP2379533A4 (en) | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFON COMPOUNDS WITH CB2 RECEPTOR AGONIST EFFECT | |
| ZA200808078B (en) | Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity | |
| BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
| BRPI0815797A2 (pt) | Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu | |
| IL209318A0 (en) | Bicyclic compounds having activity at the cxcr4 receptor | |
| PL3733665T3 (pl) | Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4 | |
| EP2598161A4 (en) | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH STABILIZED REGIONS | |
| ZA202213427B (en) | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | |
| GB2603330B (en) | Heterocyclic THR-B receptor agonist compound and preparation method and use therefor | |
| ZA201005826B (en) | Selective agonist of toll-like receptor 3 | |
| HK40108225A (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| GB202105846D0 (en) | GPR35 Agonist compounds | |
| GB202016152D0 (en) | Linear Apelin Receptor Agonist | |
| GB202110135D0 (en) | Muscarinic receptor agonists | |
| GB202105847D0 (en) | GPR35 Agonist compounds | |
| GB201909002D0 (en) | Prostaglandin EP4 receptor agonist compounds | |
| GB201909004D0 (en) | Prostaglandin EP4 receptor agonist compounds | |
| GB201909012D0 (en) | Prostaglandin EP4 receptor agonist compounds | |
| GB202111104D0 (en) | Prostaglandin EP4 receptor agonist compounds | |
| GB202111133D0 (en) | Prostaglandin ep4 receptor agonist compounds | |
| GB202111114D0 (en) | Prostaglandin EP4 receptor agonist compounds | |
| GB202005550D0 (en) | GPR35 agonist compounds | |
| GB202005549D0 (en) | GPR35 agonist compounds |